BCAXBicara Therapeutics Inc.

1. Aug 25, 2026On August 21, 2026, Bicara Therapeutics Inc. (the “Company”) entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC, as sublandlord (the “Sublandlord”), pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located …Material agreement entered · Form 8-K
2. Jul 28, 2026Resignation of Kiran Mazumdar-Shaw On July 23, 2026, Kiran Mazumdar-Shaw resigned from the Board of Directors (the “Board”) of Bicara Therapeutics Inc. (the “Company”) and her position on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as …Director or officer change · Form 8-K
3. Feb 26, 2026On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”) …Material agreement entered · Form 8-K
4. Dec 8, 2025On December 6, 2025, the Company announced preliminary data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in first-line human papillomavirus-negative recurrent/metastatic (“R/M”) head and neck squamous cell carcinoma (“HNSCC”)Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.